51 Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Comprehensive Meta-Analysis

Track: BMT Tandem "Scientific" Meeting
Saturday, February 14, 2015, 4:45 PM-6:45 PM
Seaport Ballroom DE (Manchester Grand Hyatt)
Natasha Kekre, MD, FRCPC , Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
Kimberley Mak, MD , Harvard Radiation Oncology Program, Boston, MA
Konrad Stopsack , Harvard School of Public Health, Boston, MA
Kazusa Ishii, MD, MPH , National Institutes of Health, Bethesda, MD
Moritz Binder , Harvard School of Public Health, Boston, MA
Elsa Brånvall , Karolinska University Hospital, Stockholm, Sweden
Corey S. Cutler, MD , Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Background: Mismatched unrelated donor (MMURD) transplantation is widely used in patients who lack a matched unrelated donor (MUD). Despite several published observational studies, the magnitude of risk associated with 9 out of 10 MMURD transplant and that of HLA-specific mismatches is still unclear. We performed a meta-analysis to assess the difference in outcomes of MUD to those of MMURD transplant.

Methods: A comprehensive search of Medline and EMBASE was performed through April 2014. We included published manuscripts that reported outcomes of adult patients with hematologic malignancies who underwent MUD (matched at HLA-A, B, C and DRB1 at a minimum) or MMURD transplant (single antigen or allele mismatch only). The pooled relative risks (RR) from hazard ratios and risk ratios and 95% confidence intervals (CI) were estimated using a DerSimonian-Laird random-effects model. Heterogeneity was tested using the I2 statistic and Cochran Q test, and sources of heterogeneity were evaluated using univariate meta-regression. Statistical analyses were performed using Stata v13.1.

Results: Twenty-two studies were included, representing 38,877 transplants. Nine out of 10 MMURD transplant was associated with a higher risk of overall mortality compared with 10 out of 10 MUD transplant (n=10; RR 1.32, 95% CI 1.17–1.49). No significant sources of heterogeneity were identified. MMURD transplant was associated with worse disease-free survival compared with MUD transplant (n=6; RR 1.20, 95% CI, 1.08–1.33). The pooled effect estimates for grade II-IV acute and chronic GVHD were 1.23 (n=4; 95% CI 0.99–1.53) and 1.08 (n=3; 95% CI 0.76–1.54) respectively. Single antigen/allele mismatches at HLA-A, B, C or DRB1 were associated with a higher risk of grade III-IV acute GVHD and overall mortality, but not chronic GVHD as compared with MUD transplant (Table). Disease-free survival was only worse for HLA-B mismatch.

Conclusion: MMURD transplant is associated with significantly higher risk of overall mortality and acute GVHD, but not chronic GVHD compared with MUD transplant. This risk is associated with HLA-A, -B, -C, and –DRB1, but not -DQB1 and -DPB1 mismatches. 

Pooled RR

(95% CI)

Grade II-IV

Acute GVHD

Grade III-IV

Acute GVHD

Chronic

GVHD

Disease-Free

Survival

Overall

Survival

HLA-A

1.12 (0.75 - 1.66)

1.57 (1.29 - 1.90)

0.99 (0.68 - 1.45)

1.20 (1.00 - 1.45)

1.47 (1.31 - 1.65)

HLA-B

1.41 (0.63 - 3.12)

1.67 (1.37 - 2.03)

0.87 (0.56 - 1.36)

1.20 (1.04 - 1.38)

1.33 (1.18 - 1.51)

HLA-C

1.16 (1.04 - 1.28)

1.44 (1.25 - 1.65)

1.04 (0.94 - 1.16)

1.01 (0.73 - 1.38)

1.28 (1.13 - 1.46)

HLA-DRB1

1.60 (1.23 - 2.09)

1.39 (1.13 - 1.72)

1.11 (0.68 - 1.83)

1.16 (0.94 - 1.44)

1.36 (1.22 - 1.51)

HLA-DQB1

0.89 (0.37 - 2.14)

insufficient data

insufficient data

0.99 (0.71 - 1.37)

0.95 (0.69 - 1.31)

HLA-DPB1

2.68 (1.16 - 6.19)

1.20 (0.94 - 1.52)

1.06 (0.76 - 1.46)

0.85 (0.75 - 0.97)

0.98 (0.89 - 1.07)

Disclosures:
C. S. Cutler, Takeda, Advisor: Consultancy
Pharmacyclics, Advisor: Consultancy
Fate , Advisor: Advisory Board
Idera, Advisor: Advisory Board